clinical trial · NCT07225816
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Novo Nordisk A/S·phase1·recruiting·n = 75
ObesityLiraglutideOral SemaglutideSemaglutide
brief summary
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
started
Nov 7, 2025
primary completion
Jun 19, 2026
completion
Jul 17, 2026
last updated
Jun 16, 2026
official title
Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol